Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 124935
Published online Nov 24, 2026. doi: 10.5306/wjco.124935
Published online Nov 24, 2026. doi: 10.5306/wjco.124935
Table 1 Clinical characteristics of HN1 L expression in patients from Sun Yat-sen University Cancer Center cohort, n (%)/mean ± SD/median (min-max)
| HN1 L-low (n = 42) | HN1 L-high (n = 42) | P value | |
| Age | |||
| 54.4 ± 9.22 | 52.0 ± 13.0 | 0.34 | |
| 55.0 (34.0-75.0) | 51.5 (25.0-77.0) | ||
| Sex | |||
| Female | 15 (35.7) | 19 (45.2) | 0.505 |
| Male | 27 (64.3) | 23 (54.8) | |
| BMI | |||
| 22.5 ± 3.58 | 22.1 ± 2.99 | 0.524 | |
| 22.2 (15.4-30.9) | 21.7 (16.8-28.9) | ||
| MMR status | |||
| dMMR | 5 (11.9) | 3 (7.1) | 0.909 |
| pMMR | 26 (61.9) | 23 (54.8) | |
| Missing | 11 (26.2) | 16 (38.1) | |
| OS outcome | |||
| Alive | 40 (95.2) | 38 (90.5) | 0.672 |
| Dead | 2 (4.8) | 4 (9.5) | |
| OS follow-up time | |||
| 62.4 ± 18.1 | 54.6 ± 26.1 | 0.116 | |
| 63.8 (32.6-98.4) | 51.1 (12.6-100) | ||
| DFS outcome | |||
| Disease-free | 34 (81.0) | 36 (85.7) | 0.77 |
| Recurrence or death | 8 (19.0) | 6 (14.3) | |
| DFS follow-up time | |||
| 57.1 ± 21.4 | 52.0 ± 26.7 | 0.34 | |
| 56.2 (13.7-98.4) | 48.4 (5.10-100) | ||
| TNM stage | |||
| I | 4 (9.5) | 3 (7.1) | 0.923 |
| II | 30 (71.4) | 31 (73.8) | |
| III | 8 (19.0) | 8 (19.0) | |
| CEA | |||
| 22.0 ± 109 | 7.27 ± 10.6 | 0.388 | |
| 2.98 (0.231-708) | 2.85 (0.460-55.4) | ||
| CA19-9 | |||
| 57.6 ± 125 | 82.4 ± 284 | 0.607 | |
| 15.6 (0.600-592) | 16.0 (0.600-1820) | ||
| Chemotherapy | |||
| No | 17 (40.5) | 14 (33.3) | 0.651 |
| Yes | 25 (59.5) | 28 (66.7) |
- Citation: Kang D, Zeng LX, Zhang RX, Ma WJ, Yang R, Wang X. HN1 L promotes colorectal cancer proliferation and migration by inhibiting the Hippo pathway. World J Clin Oncol 2026; 17(11): 124935
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/124935.htm
- DOI: https://dx.doi.org/10.5306/wjco.124935